Bildkälla: Stockfoto

Elicera Therapeutics: First patient included in ELC-301 CARMA (phase I/II) study - Redeye

Redeye gives a brief comment on today’s news that the first patient has been included in the ELC-301 CARMA (I/IIa) study.

Redeye gives a brief comment on today’s news that the first patient has been included in the ELC-301 CARMA (I/IIa) study.
Börsvärldens nyhetsbrev
ANNONSER